Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection

Am J Ophthalmol. 2000 Jul;130(1):126-7. doi: 10.1016/s0002-9394(00)00486-4.

Abstract

Purpose: To report a case of anterior uveitis and ocular hypotony during HPMPC treatment of a cytomegalovirus infection without ophthalmic involvement.

Methods: A 61-year-old bisexual white man with AIDS presented with moderate anterior uveitis and ocular hypotony after 8 weeks of intravenous HPMPC and oral probenecid co-treatment of a presumed recurrence of cytomegalovirus encephalitis.

Results: There was no evidence of an ocular cytomegalovirus infection. Cidofovir-related uveitis was diagnosed, and the HPMPC-probenecid co-treatment was switched to ganciclovir monotherapy. The ocular inflammation was successfully managed with topical steroids and mydriatics.

Conclusions: This description of ophthalmic side effects from systemic HPMPC in the absence of ocular cytomegalovirus infection supports the hypothesis that anterior uveitis and ocular hypotony result from a direct interaction between the drug and the ciliary body.

Publication types

  • Case Reports

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Cidofovir
  • Cytomegalovirus Infections / drug therapy*
  • Cytosine / adverse effects*
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Intraocular Pressure / drug effects
  • Male
  • Middle Aged
  • Ocular Hypotension / chemically induced*
  • Organophosphonates*
  • Organophosphorus Compounds / adverse effects*
  • Organophosphorus Compounds / therapeutic use
  • Probenecid / therapeutic use
  • Uveitis, Anterior / chemically induced*

Substances

  • Antiviral Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Cytosine
  • Cidofovir
  • Probenecid